Internal Medicine, Medical Oncology · San Antonio, TX
NPI
1396078291
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
202 Baltimore
San Antonio, TX, 78215
Phone (210) 299-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
391,970 services
Medicare patients, 2024
514
Average age 75
Drug cost, 2024
$2.7M
1,913 prescriptions
Company payments, 2025
$4,235
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sreecharan Reddy Mavuram was code Q5125 (injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram), 115,680 times for 18 patients. In total Sreecharan Reddy Mavuram billed 391,970 services in 115 codes, and Medicare paid $4.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 115,680 | 18 | $0.38 | $44K |
| J1756 Injection, iron sucrose, 1 mg | Office | 22,200 | 25 | $0.17 | $3,860 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 19,800 | 15 | $0.11 | $2,227 |
| J0897 Injection, denosumab, 1 mg | Office | 13,740 | 47 | $20.56 | $283K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 8,180 | 31 | $6.52 | $53K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 7,414 | 86 | $0.09 | $667 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 5,786 | 32 | $0.07 | $429 |
| J1576 Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 3,500 | 12 | $52.23 | $183K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,060 | 18 | $5.71 | $12K |
| 96367 Intravenous Infusion, Hydration | Office | 1,961 | 103 | $21.04 | $41K |
| 99214 Office E&M - Established | Office | 1,610 | 448 | $88.73 | $143K |
| J0612 Injection, calcium gluconate, not otherwise specified, 10 mg | Office | 1,489 | 24 | $0.03 | $51.08 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,300 | 11 | $14.99 | $19K |
| 96372 Injection Administration | Office | 751 | 105 | $10.49 | $7,877 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 613 | 90 | $0.64 | $393 |
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 38 | 34 | $8.65 | $329 |
Medicare prescription drug claims, 2024
In 2024, the drug Sreecharan Reddy Mavuram prescribed most often to Medicare patients was Anastrozole, with 195 prescriptions and refills. In total Sreecharan Reddy Mavuram wrote 1,913 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 195 | 479 | 67 | $2,726 |
| Warfarin Sodium Generic | 94 | 206 | 21 | $572 |
| Gabapentin Generic | 85 | 128 | 20 | $1,142 |
| Acyclovir Generic | 72 | 170 | 24 | $972 |
| Hydroxyurea Generic | 65 | 113 | 15 | $1,780 |
| Ondansetron Odt Ondansetron | 62 | 62 | 48 | $1,950 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 62 | 62 | 20 | $1,152 |
| Xarelto Rivaroxaban | 51 | 122 | 19 | $67K |
| Alendronate Sodium Generic | 44 | 124 | 21 | $230 |
| Prednisone Generic | 39 | 48 | 25 | $152 |
| Zarxio Filgrastim-Sndz | 39 | 39 | 16 | $169K |
| Folic Acid Generic | 36 | 93 | 13 | $333 |
| Letrozole Generic | 36 | 72 | 14 | $670 |
| Jakafi Ruxolitinib Phosphate | 33 | 33 | Under 11 | $527K |
| Pantoprazole Sodium Generic | 32 | 54 | 16 | $171 |
Brand drugs: 284 claims; generic drugs: 1,629 claims; opioid claims: 146.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sreecharan Reddy Mavuram $4,235 ($4,235 in general payments such as food, travel and fees) from 40 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $443.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 18 | $443 |
| Janssen Biotech, Inc. JNJ | 12 | $309 |
| Merck Sharp & Dohme LLC MRK | 10 | $260 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $245 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $245 |
| Daiichi Sankyo Inc. 4568.T | 10 | $226 |
| Celgene Corporation BMY | 9 | $204 |
| Pfizer Inc. PFE | 11 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $157 |
| Genentech USA, Inc. ROG.SW | 6 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.